Lexicon Genetics

Lexicon Genetics is a biotechnology company focused on utilizing genetic research to develop innovative therapies and diagnostic tools for various diseases and conditions. Founded in 1995, Lexicon Genetics specializes in the application of genetic research to enhance healthcare solutions. The company raised USD 35 mn in funding in August 2012. Johnson Eva, the founder, has a history of involvement in the biotechnology sector, although specific details about previous ventures are not available.

Lexicon Genetics develops a variety of therapeutic products and diagnostic tools aimed at addressing unmet medical needs. Their offerings leverage advanced genetic insights to create innovative solutions for healthcare challenges, targeting areas such as rare diseases and chronic conditions. The company primarily serves the healthcare sector, with a focus on bringing new products to market that utilize their proprietary genetic technologies. In 2024, Lexicon Genetics reported a revenue of USD 31.

08 mn, while its EBITDA for the same year was USD -181. 24 mn, indicating significant investments in research and development as they pursue new therapeutic avenues. Lexicon Genetics plans to utilize the recent financing of USD 35 mn to support the development of new products and expand its market reach. The company is targeting the launch of innovative therapeutics that are currently in the design phase, with expected releases in the coming years.

They are also looking to expand into new geographic markets, particularly in Europe and Asia, by 2025, which will be facilitated by funding aimed at enhancing their operational capabilities and research initiatives.